Join us for ODACon 2022!


ODACon 2022

The Oncology Data Advisor Supportive Care Summit brings together world-renowned faculty to discuss and debate best practices in oncology supportive care. This year’s event will provide expert perspectives and guidance on evidence-based supportive care for patients receiving novel breast cancer therapies, including the following:

  • Antibody-drug conjugates
  • CDK4/6 inhibitors
  • HER2 tyrosine kinase inhibitors
  • Immune checkpoint inhibitors
  • Monoclonal antibodies
  • PARP inhibitors
  • PI3K inhibitors
  • And more!

Please join us for an exciting and interactive robust online (web and mobile) professional development experience, featuring live video sessions, audience polling with real-time analytics, an interactive community message board, and small group learner-faculty networking sessions.  

Participants may receive 5.5 AMA PRA Category 1 Credit™/MOC Points/ANCC contact hours/ACPE contact hours/ILNA upon completion of the activity evaluation.

FACULTY PREVIEW

In the preview video below, hear from our expert faculty for ODACon 2022! They provide a great overview, their personal experience, and the topics they will be discussing for this exciting conference.


National Breast Cancer Foundation®

We are pleased to have the National Breast Cancer Foundation partner with us for ODACon™ 2022 Supportive Care Summit!

Recognized as one of the leading breast cancer organizations in the world, National Breast Cancer Foundation (NBCF) is Helping Women Now® by providing early detection, education, and support services to those affected by breast cancer. A recipient of Charity Navigator’s highest 4-star rating for 16 years, NBCF provides support through their National Mammography Program, Patient Navigation, breast health education, and patient support programs. For more information, please visit https://www.nationalbreastcancer.org.


Sessions

Breast cancer is the most common tumor type among women in the United States, accounting for nearly 30% of cancer diagnoses. While earlier detection and novel therapies have improved survival in recent years, treatment-related toxicities continue to impact quality of life (ACS, 2022). Because toxicities often vary by class of drug prescribed, comprehensive knowledge of each novel therapy class—antibody-drug conjugates, CDK4/6 inhibitors, HER2 tyrosine kinase inhibitors, immune checkpoint inhibitors, monoclonal antibodies, PARP inhibitors, and PI3 kinase inhibitors—are critical to providing optimal patient-centered care.

In this live symposium, our estemeed nurse faculty will provide expert guidance on the management and supportive care of patients receiving these novel therapies for breast cancer. For an indepth look at each session please CLICK HERE.


Speakers

We are so pleased to announce the exceptional speakers who will be presenting at ODACon 2022. Throughout the conference attendees will have the opportunity to hear from our panel of distinguished faculty experts during 7 case-based interactive sessions. CLICK HERE to learn more about our esteemed faculty.


Schedule of Events


Pricing


Sponsors


Supporters

This activity is supported by independent grants from Gilead Sciences, Inc. and Puma Biotechnology, Inc.


Copyright © 2022 i3 Health. All rights reserved.